A literature review on Janus kinase (JAK) inhibitors for the treatment of immunobullous disorders

Kalantari, Yasamin; Sadeghi, Sara; Asadi, Delaram; Goodarzi, Azadeh

doi:10.1016/j.intimp.2022.108923

Cited by 12 publications

(7 citation statements)

References 26 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…There is existing evidence to support therapeutic rationale for the use of JAKi in BP and other immune-mediated bullous diseases, including higher expression of JAK/STAT proteins in skin lesions in BP and other immunobullous diseases compared with healthy subjects, as well as activation of JAK/STAT signalling pathway in the pathogenesis of pemphigoid. 5,6 A recent review by Kalantari et al 7 summarises the use of various JAKi for the treatment of other immunobullous disorders (mucous membrane pemphigoid, dermatitis herpetiformis, and epidermolysis bullosa) which supports the rationale for JAKi as a promising short-term therapeutic option to achieve rapid disease control and help mitigate disturbances in immunotherapy regimens in DIBP. This is the only case to our knowledge documenting use of a JAKi, upadacitinib, for the treatment of BP and offers early support for its therapeutic potential in refractory cases.…”

Section: Discussionmentioning

confidence: 95%

A case of drug-induced bullous pemphigoid secondary to immunotherapy treated with upadacitinib: A case report

Gresham

Kirchhof

2023

SAGE Open Medical Case Reports

View full text Add to dashboard Cite

Bullous pemphigoid is an acquired autoimmune subepidermal blistering disease that can arise following exposure to systemic medication, referred to as drug-induced bullous pemphigoid. Drug-induced bullous pemphigoid is a rare but potentially serious immune-related adverse event that should be considered in patients with advanced malignancies undergoing immunotherapy, with immune checkpoint inhibitors emerging in particular as a well-documented drug association in drug-induced bullous pemphigoid. We present a 74-year-old female with recurrent metastatic programmed cell death-ligand 1–positive squamous cell carcinoma of the head and neck area who developed drug-induced bullous pemphigoid in the setting of immunotherapy with a novel immunoglobulin-like transcript 4 inhibitor (MK-4830) in combination with pembrolizumab. Treatment with upadacitinib, a Janus-associated kinase-1 inhibitor, was pursued for significantly disabling disease that was recalcitrant to standard therapies and ultimately transition to palliative care. Follow-up at 4 weeks demonstrated good response. This is the first report describing the use of a Janus-associated kinase inhibitor for the treatment of bullous pemphigoid.

show abstract

Section: Discussionmentioning

confidence: 95%

A case of drug-induced bullous pemphigoid secondary to immunotherapy treated with upadacitinib: A case report

Gresham

Kirchhof

2023

SAGE Open Medical Case Reports

View full text Add to dashboard Cite

show abstract

“…The following table shows representative compounds tested for JAK1 inhibition and the biological data obtained from testing representative examples. For IC 50 , “A” means <10 nM, “B” means 10–50 nM, and “C” means >50 nM. …”

Section: Important Compound Classesmentioning

confidence: 99%

Boron-Containing Pyrazole Compounds as JAK Inhibitors for Treating Inflammation, Autoimmune Diseases, and Cancer

Sabnis¹

2022

ACS Med. Chem. Lett.

View full text Add to dashboard Cite

show abstract

“…JAKi are a novel therapeutic option for the treatment of AD, targeting proteins in the Janus kinase‐signal transducer and activator of transcription (JAK–STAT) pathway. JAKi can be used orally or topically to inhibit the JAK–STAT pathway and decrease the production of downstream cytokines 8,9 . JAK proteins are intracellular tyrosine kinase attached to many cytokines' receptors.…”

Section: Introductionmentioning

confidence: 99%

“…JAKi can be used orally or topically to inhibit the JAK-STAT pathway and decrease the production of downstream cytokines. 8,9 JAK proteins are intracellular tyrosine kinase attached to many cytokines' receptors. There are four different isoforms of JAK proteins, including JAK1, JAK2, JAK3 and TYK2 (tyrosine kinase).…”

mentioning

confidence: 99%

Efficacy and safety of topical JAK inhibitors in the treatment of atopic dermatitis in paediatrics and adults: A systematic review

Sadeghi

Mohandesi

2023

Experimental Dermatology

Self Cite

View full text Add to dashboard Cite

Atopic dermatitis is a common chronic inflammatory condition of skin with a complex aetiology, resulting from the interplay of genetic predisposition, innate and adaptive immune system responses and environmental factors. 1,2 AD prevalence rate is approximately 20% in children and 10% in adults worldwide and has a significant negative impact on the quality of life due to intense pruritus and relapsing course. 3 There are three different types of atopic dermatitis: the persistent type, in which AD starts in childhood and persists; the relapsing type, in which AD appears during childhood with symptom-free intervals until adulthood; the adult-onset type,

show abstract

A literature review on Janus kinase (JAK) inhibitors for the treatment of immunobullous disorders

Cited by 12 publications

References 26 publications

A case of drug-induced bullous pemphigoid secondary to immunotherapy treated with upadacitinib: A case report

A case of drug-induced bullous pemphigoid secondary to immunotherapy treated with upadacitinib: A case report

Boron-Containing Pyrazole Compounds as JAK Inhibitors for Treating Inflammation, Autoimmune Diseases, and Cancer

Efficacy and safety of topical JAK inhibitors in the treatment of atopic dermatitis in paediatrics and adults: A systematic review

Contact Info

Product

Resources

About